In This Article:
Genelux (NASDAQ:GNLX) Full Year 2024 Results
Key Financial Results
-
Net loss: US$29.9m (loss widened by 5.6% from FY 2023).
-
US$0.95 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Genelux Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 67%. Earnings per share (EPS) missed analyst estimates by 8.6%.
Looking ahead, revenue is forecast to grow 64% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 22% from a week ago.
Risk Analysis
Be aware that Genelux is showing 4 warning signs in our investment analysis and 2 of those are a bit concerning...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
